Melanoma in situ: Part II. Histopathology, treatment, and clinical management

doi:10.1016/j.jaad.2015.03.057

Journal of the American Academy of Dermatology

Volume 73, Issue 2, August 2015, Pages 193-203

https://doi.org/10.1016/j.jaad.2015.03.057 Get rights and content

Melanoma in situ (MIS) poses special challenges with regard to histopathology, treatment, and clinical management. The negligible mortality and normal life expectancy associated with patients with MIS should guide treatment for this tumor. Similarly, the approach to treatment should take into account the potential for MIS to transform into invasive melanoma, which has a significant impact on morbidity and mortality. Part II of this continuing medical education article reviews the histologic features, treatment, and management of MIS.

Section snippets

Histopathology of melanoma in situ

Key points

•
The histopathologic diagnosis of melanoma in situ can be difficult
•
Immunohistochemical stains may aid in the diagnosis by highlighting junctional melanocytes
•
Microphthalmia transcription factor (MITF) and SOX10 are emerging as the preferred immunohistochemical stains to aid in the diagnosis of melanoma in situ
•
Atypical melanocytic hyperplasia in the setting of sun-damaged skin represents an important diagnostic challenge and can be difficult to differentiate from early melanoma in situ,

Current recommendations and trends in the treatment of melanoma in situ

Key points

•
Excisional margins of 0.5 cm are considered the standard treatment for melanoma in situ, but the lack of randomized controlled trials supporting this standard is noteworthy
•
There is evidence to support wider margins (ranging between 0.5-1.0 cm)

Because of the potential of MIS to transform into malignant melanoma (MM) and the possibility of sampling error in biopsy specimens of larger melanocytic lesions, excision with at least 0.5-cm margins is recommended.10, 11, 12 Based on Surveillance,

Upstaging to malignant melanoma

Key points

•
Based on the literature, a range of 5% to 29% of melanoma in situ cases are upstaged to invasive malignant melanoma after review of the pathology specimen obtained from complete excision
•
Upstaging occurs more frequently after shave biopsy specimens

In a review of the literature, approximately 5% to 29% of MIS lesions actually proved to have at least 1 focus of invasion upon surgical excision. This finding upstaged the initial diagnosis of MIS to MM, but varied widely because of study sample

Treatment: Surgical removal

Key points

•
Surgical removal may be performed by wide local excision, staged excision with expedited permanent sections, or Mohs micrographic surgery
•
Margins of 0.5 to 0.6 cm result in varying clearance rates and wider margins may be necessary for tumor removal

Various surgical options can be used for the treatment of MIS. These include wide local excision (WLE), staged excision, and Mohs micrographic surgery (MMS). WLE aims to remove the clinically apparent tumor and a surrounding margin of normal tissue.

Staged excision

Key points

•
Staged excision is a means of improving margin control through sequential surgical removal of tissue after examination of the edges by pathology using permanent sections
•
Methods of staged excision include the square technique and the spaghetti technique

Occasionally, because of the finding of positive margins after initial excision, additional tissue needs to be removed. Staged surgical excision with permanent section avoids the limitations of removal by MMS, which is an approach that has not yet

Mohs micrographic surgery

Key points

•
Mohs surgery for melanoma in situ has shown variable clearance rates and success
•
Because of the difficulty of accurately visualizing melanocytes on frozen sections, its success is dependent on the skill of the technician and surgeon
•
Immunohistochemical stains have been employed to better delineate melanocytes on frozen sections

In order to preserve tissue in locations where MIS frequently occurs, some have proposed using the Mohs microscopically controlled surgery approach. In this method,

Imiquimod

Key points

•
Imiquimod is not FDA approved for the treatment of melanoma in situ; its use is therefore considered off-label
•
Clearance rates with imiquimod can vary widely

There are several case reports and open-label studies of the use of imiquimod 5% cream for treatment of MIS, LM subtype.⁵⁵ Imiquimod is an immune response modifier that works by activating Toll-like receptor 7 (TLR-7) and causes a localized immune response at the targeted site(s). It is approved by the US Food and Drug Administration for the

Radiation

Key point

•
There are limited studies on the use of radiation for melanoma in situ

There are a limited number of studies investigating the use of radiation for MIS. Grenz rays and fractionated radiotherapy have varying degrees of success.97, 98 Recurrence rates range from 0% to 20%, and side effects include radiation dermatitis, telangiectasias, hypo- or hyperpigmentation, erythema, and the development of other neoplasms, such as basal and squamous cell carcinoma.98, 99, 100, 101, 102 Radiation therapy is

Laser therapy

Key point

•
Recurrence after laser therapy can be as high as 38%

Several lasers have been used to treat MIS in case reports and case series. These lasers include CO₂, Q-switched neodymium-doped yttrium aluminium garnet, Q-switched ruby, argon, and alexandrite. Combinations of these laser modalities have also been tried. The largest case series involved 22 patients treated with the Q-switched neodymium-doped yttrium aluminium garnet laser. Recurrence rates were 23% after a follow-up of <3 months.¹⁰³ When

References (122)

K. Madden et al.
Quantification of melanocytes in sun-damaged skin
J Am Acad Dermatol
(2011)
J.F. Thompson et al.
Cutaneous melanoma
Lancet
(2005)
C.K. Bichakjian et al.
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology
J Am Acad Dermatol
(2011)
M. Megahed et al.
Reliability of diagnosis of melanoma in situ
Lancet
(2002)
G.M. Bricca et al.
Cutaneous head and neck melanoma treated with Mohs micrographic surgery
J Am Acad Dermatol
(2005)
J.H. Kunishige et al.
Surgical margins for melanoma in situ
J Am Acad Dermatol
(2012)
S. Akhtar et al.
Surgical excision margins for melanoma in situ
J Plast Reconstr Aesthet Surg
(2014)
J.K. Robinson
Margin control for lentigo maligna
J Am Acad Dermatol
(1994)
T.M. Johnson et al.
Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure
J Am Acad Dermatol
(1997)
C. Gaudy-Marqueste et al.
The “spaghetti technique”: an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma)
J Am Acad Dermatol
(2011)

N. Agarwal-Antal et al.

Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines

J Am Acad Dermatol

(2002)

C. Hazan et al.

Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases

J Am Acad Dermatol

(2008)

H.W. Walling et al.

Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma

J Am Acad Dermatol

(2007)

J.A. Zitelli et al.

The reliability of frozen sections in the evaluation of surgical margins for melanoma

J Am Acad Dermatol

(1991)

I. Kupfer-Bessaguet et al.

Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation

J American Acad Dermatol

(2004)

A.M. Powell et al.

Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy

J Am Acad Dermatol

(2004)

J.E. Osborne et al.

A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision

Br J Plast Surg

(2002)

H. Leibl et al.

Inhibition of DNA synthesis of melanoma cells by azelaic acid

J Invest Dermatol

(1985)

M. Nazzaro-Porro et al.

Effect of dicarboxylic acids on lentigo maligna

J Invest Dermatol

(1979)

S. Chimenti et al.

Treatment of lentigo maligna with tazarotene 0.1% gel

J Am Acad Dermatol

(2004)

M.H. Schmid-Wendtner et al.

Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients

J Am Acad Dermatol

(2000)

C.A. Barker et al.

Radiation therapy for cutaneous melanoma

Dermatol Clin

(2012)

M.A.L. Tan et al.

Criteria for histopathologic diagnosis of melanoma, 1947-2000: a critique in historical perspective

Dermatopathol Pract Conceptual

(2001)

J.N. Buonaccorsi et al.

Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases

Am J Dermatopathol

(2014)

J. Kim et al.

Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ

J Cutan Pathol

(2011)

C.Y. Silva et al.

Nests with numerous SOX10 and MiTF-positive cells in lichenoid inflammation: pseudomelanocytic nests or authentic melanocytic proliferation?

J Cutan Pathol

(2011)

J.O. Barlow et al.

The density and distribution of melanocytes adjacent to melanoma and nonmelanoma skin cancers

Dermatol Surg

(2007)

W. Weyers et al.

Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis

Am J Dermatopathol

(1996)

R.A. Scolyer et al.

Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis

Australas J Dermatol

(2006)

V.G. Prieto et al.

Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?

Am J Clin Pathol

(2003)

H. Tsao et al.

Management of cutaneous melanoma

N Engl J Med

(2004)

NCCN guidelines for melanoma

(2014)

B.B. Kroon et al.

Consensus on the management of malignant melanoma of the skin in The Netherlands. Dutch Melanoma Working Party

Melanoma Res

(1999)

A.J. Sober

Diagnosis and management of early melanoma: a consensus view

Semin Surg Oncol

(1993)

National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992

Am J Dermatopathol

(1993)

Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29, 1992

Consens Statement / NIH Consensus Development Conference National Institutes of Health Consensus Development Conference

(1992)

S. Mocellin et al.

Cutaneous melanoma in situ: translational evidence from a large population-based study

Oncologist

(2011)

Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management...

C.A. Charles et al.

Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists

Arch Dermatol

(2005)

M.J. Zalla et al.

Mohs micrographic excision of melanoma using immunostains

Dermatol Surg

(2000)

S.C. Somach et al.

Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens

Arch Dermatol

(1996)

D. Weedon

A reappraisal of melanoma in situ

J Dermatol Surg Oncol

(1982)

G.L. Egnatios et al.

The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma

Am J Surg

(2011)

J.G. Albertini et al.

Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique

Dermatol Surg

(2002)

T.N. Bienert et al.

Treatment of cutaneous melanoma of the face by Mohs micrographic surgery

J Cutan Med Surg

(2003)

Diagnosis and treatment of early melanoma

JAMA

(1992)

T. Tzellos et al.

Interventions for melanoma in situ, including lentigo maligna

Cochrane Database Syst Rev

(2014)

J.L. Bub et al.

Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up

Arch Dermatol

(2004)

G.S. Clark et al.

Surgical management of melanoma in situ on chronically sun-damaged skin

Cancer Control

(2008)

M. Abdelmalek et al.

Geometric staged excision for the treatment of lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review

Arch Dermatol

(2012)

Cited by (56)

Topical delivery of nanoemulsions for skin cancer treatment
2023, Applied Materials Today
Skin cancer chemotherapeutics often lead to the development of severe cytotoxicity, compelling the development of novel delivery systems to not only enhance therapeutic efficacy but also minimize side effects and improve patient compliance. In recent years, topical nanoemulsions have emerged as powerful tools in the field of skin cancer therapeutic management. This review delves into the potential of these innovative formulations to revolutionize the treatment of skin malignancies, due to their unique properties, having relevant advantages, such as allowing high drug strength, skin drug permeation and retention enhancement, biocompatibility, and controlled release capacity. Despite the skin's formidable permeability challenges, it remains an accessible interface for the delivery of therapeutic carriers such as nanoemulsions both locally (topical and dermal) and systemically (transdermal). Nanoemulsions, once associated primarily with cosmetic applications, are now gaining prominence as essential components of skin cancer treatment strategies. This review explores the potential of topical nanoemulsions, shedding light on their ability to efficiently deliver a wide range of molecules, overcoming lipophilic barriers inherent to skin. In this comprehensive analysis of several distinct studies investigating NEs for skin cancer treatment, a diverse array of formulations and components were explored, revealing a spectrum of characteristics. The PDI spans from a minimum of 0.105 nm to a maximum of 0.421 nm, reflecting variations in droplet size distribution. Droplet sizes exhibit considerable diversity, ranging from a small 16 nm to a larger 200 nm, signifying varied potential for skin penetration. ZP values further contribute to this diversity, ranging from highly favorable (-66.6 mV) to less advantageous or near zero values, indicative of distinct surface charge characteristics. As healthcare costs continue to escalate, this nuanced overview of nanoemulsion characteristics provides valuable insights into their potential applications in the targeted treatment of melanoma and, to a lesser extent, non-melanoma skin cancers. The value of such innovative and safer drug delivery systems becomes increasingly evident. Here, we focus exclusively on the role of topical nanoemulsions in advancing skin cancer therapy.
Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
2023, JID Innovations
Nonkeratinocyte cutaneous malignancies, including breast cancer cutaneous metastasis and melanoma in situ, are often poor surgical candidates. Imiquimod (IMQ), a toll-like receptor 7 agonist that activates innate immunity in the skin, is used to treat these cutaneous malignancies. However, IMQ's modest effect on the activation of adaptive immunity limits its efficacy as a monotherapy. In this study, we demonstrate that topical TSLP cytokine inducers—calcipotriol and retinoic acid—synergize with IMQ to activate CD4⁺ T-cell immunity against nonkeratinocyte cutaneous malignancies. Topical calcipotriol plus IMQ treatment reduced breast tumor growth compared with calcipotriol or IMQ alone (P < 0.0001). Calcipotriol plus IMQ–mediated tumor suppression was associated with significant infiltration of CD4⁺ effector T cells in the tumor microenvironment. Notably, topical calcipotriol plus IMQ immunotherapy enabled immune checkpoint blockade therapy to effectively control immunologically cold breast tumors, which was associated with induction of CD4⁺ T-cell immunity. Topical treatment with calcipotriol plus IMQ and retinoic acid plus IMQ also blocked subcutaneous melanoma growth. These findings highlight the synergistic effect of topical TSLP induction in combination with innate immune cell activation as an effective immunotherapy for malignancies affecting the skin.
Nanodelivery systems for cutaneous melanoma treatment
2023, European Journal of Pharmaceutics and Biopharmaceutics
Cutaneous melanoma (CM) is a multifactorial disease whose treatment still presents challenges: the rapid progression to advanced CM, which leads to frequent recurrences even after surgical excision and, notably, the low response rates and resistance to the available therapies, particularly in the case of unresectable metastatic CM. Thereby, alternative innovative therapeutic approaches for CM continue to be searched.
In this review we discuss relevant preclinical research studies, and provide a broad-brush analysis of patents and clinical trials which involve the application of nanotechnology-based delivery systems in CM therapy.
Nanodelivery systems have been developed for the delivery of anticancer biomolecules to CM, which can be administered by different routes. Overall, nanosystems could promote technological advances in several therapeutic modalities and can be used in combinatorial therapies.
Nevertheless, the results of these preclinical studies have not been translated to clinical applications. Thus, concerted and collaborative research studies involving basic, applied, translational, and clinical scientists need to be performed to allow the development of effective and safe nanomedicines to treat CM.
Second primary malignancies in patients with melanoma in situ: Insights from the surveillance, epidemiology, and end results program
2021, Cancer Epidemiology
Citation Excerpt :
Melanoma in situ (MIS) – defined as melanoma limited to the epidermis [3] – accounts for the majority of the increase in melanoma cases [4]. Early detection and excision typically results in an excellent prognosis [5–7]. However, emerging evidence suggests that a diagnosis of MIS is associated with an increased risk of developing a second primary malignancy (SPM) [8–10].
Melanoma in situ (MIS) is among the most frequently diagnosed cancers in the United States. Emerging data suggest that MIS is associated with an increased risk of developing a second primary malignancy (SPM).
To determine trends in MIS-associated SPMs and identify MIS-specific features that increase SPM risk.
In this retrospective population-based study, we identified 90,075 patients who were diagnosed with MIS between 1973 and 2015 from the Surveillance, Epidemiology, and End Results database. The risk of developing an SPM among these individuals was compared to individuals without a diagnosis of MIS. The risk of developing an SPM among patients with a diagnosis of MIS was also increased over time.
Patients with a diagnosis of MIS had an increased relative risk (RR) of developing an SPM as compared to the general population with an identical age, sex, race, and follow-up period. The RR of a metachronous malignancy in MIS patients also increased over time, as follows: 1.16 (95 % CI: 1.07–1.26), 1.19 (95 % CI: 1.14–1.23), 1.30 (95 % CI: 1.27–1.33), and 1.52 (95 % CI: 1.49–1.56) in 1973–1982, 1983–1992, 1993–2002, and 2003–2015, respectively (P < 0.05). In addition, there was a direct correlation between the number of MIS lesions and SPM risk; ≥1, ≥2, and ≥3 tumors portended a 1.5–2, 2–3, and 4–5-fold increased risk of developing an SPM, respectively.
MIS is associated with an increased risk of developing an SPM and therefore individuals with a history of MIS may benefit from close medical surveillance.
Margins of Melanoma Excision and Modifications to Standards
2020, Surgical Oncology Clinics of North America
Citation Excerpt :
Furthermore, there is debate surrounding the appropriate surgical margins in certain melanoma subtypes, as well as melanoma in situ. Melanoma in situ, defined as cutaneous melanoma confined to the epidermis, and the most common subtype, lentigo maligna, present treatment challenges owing to the tendency to have ill-defined clinical margins in addition to the often, and yet unpredictable, subclinical extension of atypical melanocytes, potentially several centimeters beyond the clinical margins.28 In patients with contraindications to surgical resection or significant cosmetic concerns owing to tumor location, alternatives include topical therapies (eg, imiquimod) or radiation.
Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma
2019, Journal of the American Academy of Dermatology
Citation Excerpt :
Margins might be difficult to delineate because lesion edges can blend with background melanocytic hyperplasia, prompting the recommendation that a control biopsy be taken from a clinically unaffected area.15 The most reproducible feature of LM is proliferation of atypical melanocytes at the dermoepidermal junction with underlying solar elastosis (Fig 5).11,13,51,71-73 DM is defined by desmoplasia, but the diagnostic requirements are controversial.
There are multiple, genetically distinct pathways that give rise to melanoma. Melanomas on sun-damaged skin (MSDS), including lentigo maligna and desmoplastic melanoma, have distinct genetic profiles and are uniquely linked to chronic ultraviolet exposure. In this article, we discuss the etiologies of lentigo maligna and desmoplastic melanoma, emerging diagnostic adjuncts that might be helpful for accurately identifying these lesions, and the clinical relevance of their frequent co-occurrence. We present unique and overlapping features of these entities and discuss challenges in MSDS management, including margin assessment, excision, and the potential role of nonsurgical therapy. Last, we address the role of immunotherapy in invasive disease. Understanding MSDS as distinct from melanoma arising on intermittently sun-exposed or sun-protected skin will ultimately help optimize patient outcomes.

View all citing articles on Scopus

: Funding sources: None.

: Conflicts of interest: None declared.

: Date of release: August 2015

: Expiration date: August 2018

View full text

Continuing medical educationMelanoma in situ: Part II. Histopathology, treatment, and clinical management

Section snippets

Histopathology of melanoma in situ

Current recommendations and trends in the treatment of melanoma in situ

Upstaging to malignant melanoma

Treatment: Surgical removal

Staged excision

Mohs micrographic surgery

Imiquimod

Radiation

Laser therapy

J Am Acad Dermatol

Lancet

J Am Acad Dermatol

Lancet

J Am Acad Dermatol

J Am Acad Dermatol

J Plast Reconstr Aesthet Surg

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J American Acad Dermatol

J Am Acad Dermatol

Br J Plast Surg

J Invest Dermatol

J Invest Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

Dermatol Clin

Criteria for histopathologic diagnosis of melanoma, 1947-2000: a critique in historical perspective

Dermatopathol Pract Conceptual

Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases

Am J Dermatopathol

Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ

J Cutan Pathol

Nests with numerous SOX10 and MiTF-positive cells in lichenoid inflammation: pseudomelanocytic nests or authentic melanocytic proliferation?

J Cutan Pathol

The density and distribution of melanocytes adjacent to melanoma and nonmelanoma skin cancers

Dermatol Surg

Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis

Am J Dermatopathol

Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis

Australas J Dermatol

Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions?

Am J Clin Pathol

Management of cutaneous melanoma

N Engl J Med

NCCN guidelines for melanoma

Consensus on the management of malignant melanoma of the skin in The Netherlands. Dutch Melanoma Working Party

Melanoma Res

Diagnosis and management of early melanoma: a consensus view

Semin Surg Oncol

National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992

Am J Dermatopathol

Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29, 1992

Consens Statement / NIH Consensus Development Conference National Institutes of Health Consensus Development Conference

Cutaneous melanoma in situ: translational evidence from a large population-based study

Oncologist

Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists

Arch Dermatol

Mohs micrographic excision of melanoma using immunostains

Dermatol Surg

Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens

Arch Dermatol

A reappraisal of melanoma in situ

J Dermatol Surg Oncol

The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma

Am J Surg

Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique

Dermatol Surg

Treatment of cutaneous melanoma of the face by Mohs micrographic surgery

J Cutan Med Surg

Diagnosis and treatment of early melanoma

JAMA

Interventions for melanoma in situ, including lentigo maligna

Cochrane Database Syst Rev

Continuing medical education
Melanoma in situ: Part II. Histopathology, treatment, and clinical management